Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT2 | Q96PD7 | 5/20 | 0.55 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.52 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.48 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.46 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | POLQ | O75417 | 1/20 | 0.43 |
| ▸ | CCNC | P24863 | 2/20 | 0.42 |
| ▸ | CDK8 | P49336 | 2/20 | 0.42 |
| ▸ | PIM1 | P11309 | 1/20 | 0.42 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.42 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.41 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14571338 | 0.86 | DGAT2 (0.46) | DGAT2CHEK1NTSR1SERPINE1KDR | |
| SCHEMBL3633318 | 0.86 | KDM4E (0.53) | DGAT2PIM1PIM2MAPK8MAPK9 | |
| SCHEMBL29802386 | 0.86 | KDM4E (0.53) | DGAT2PIM1PIM2MAPK8MAPK9 | |
| SCHEMBL2380673 | 0.85 | MCL1 (0.49) | DGAT2CHEK1NTSR1SERPINE1KDR | |
| SCHEMBL2380952 | 0.85 | DGAT2 (0.58) | DGAT2CHEK1NTSR1SERPINE1KDR | |
| SCHEMBL2380917 | 0.84 | SERPINE1 (0.47) | DGAT2CHEK1NTSR1SERPINE1KDR | |
| SCHEMBL2381295 | 0.84 | KDM4E (0.46) | DGAT2CHEK1NTSR1SERPINE1KDR | |
| SCHEMBL12245751 | 0.84 | DGAT2 (0.57) | DGAT2CHEK1KDRPIM1PIM2 | |
| SCHEMBL8442857 | 0.81 | DGAT2 (0.66) | DGAT2CHEK1SERPINE1CDK8CYP19A1 | |
| SCHEMBL2380276 | 0.81 | KDR (0.58) | DGAT2SERPINE1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8017601-B2 | Bis-aryl kinase inhibitors and method | AMGEN INC. (US) | 2011-09-13 | — | — | US | disclosed |
| US-8017601-B2 | Bis-aryl kinase inhibitors and method | AMGEN INC. (US) | 2011-09-13 | — | — | US | disclosed |
| US-8017601-B2 | Bis-aryl kinase inhibitors and method | AMGEN INC. (US) | 2011-09-13 | — | — | US | disclosed |
| EP-1896461-A2 | BIS-ARYL KINASE INHIBITORS AND THEIR USE IN THE TREATMENT OF INFLAMMATION, ANGIOGENESIS AND CANCER | Amgen Inc. (US) | 2008-03-12 | — | — | EP | disclosed |
| US-20070054903-A1 | Bis-aryl kinase inhibitors and method | AMGEN INC. (US) | 2007-03-08 | — | — | US | disclosed |
| US-20070054903-A1 | Bis-aryl kinase inhibitors and method | AMGEN INC. (US) | 2007-03-08 | — | — | US | disclosed |
| US-20070054903-A1 | Bis-aryl kinase inhibitors and method | AMGEN INC. (US) | 2007-03-08 | — | — | US | disclosed |
| WO-2007005668-A2 | BIS-ARYL KINASE INHIBITORS AND THEIR USE IN THE TREATMENT OF INFLAMMATION, ANGIOGENESIS AND CANCER | AMGEN INC. (US) | 2007-01-11 | — | — | WO | disclosed |
| WO-2007005668-A2 | BIS-ARYL KINASE INHIBITORS AND THEIR USE IN THE TREATMENT OF INFLAMMATION, ANGIOGENESIS AND CANCER | AMGEN INC. (US) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054903-A1 | Bis-aryl kinase inhibitors and method | HGF, MET, BLK | DGAT2 3636/4885SLC6A2 3438/4885SLC6A4 3654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.